Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy

Yazdani, Mona; Gholizadeh, Zahra; Nikpoor, Amin Reza; Roshan, Nema Mohamadian; Jaafari, Mahmoud Reza; Badiee, Ali

doi:10.1038/s41598-021-94250-0

Cited by 20 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be rapidly internalized by immune cells and bind to TLR9 on the surface of internal vesicles to activate intracellular signaling response ( 43 ). CpG ODN quickly activates T and B lymphocytes, promote the production of Th1-type pro-inflammatory cytokines, and directly acts on DCs through the TLR9 signaling pathway to induce the maturation/activation of DCs, which has a broad application prospect in anti-tumor therapy ( 44 ). Jie et al.…”

Section: Discussionmentioning

confidence: 99%

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

Ovarian cancer (OC) is a malignant tumor that seriously affects women’s health. In recent years, immunotherapy has shown great potential in tumor treatment. As a major contributor of immunotherapy, dendritic cells (DCs) - based tumor vaccine has been demonstrated to have a positive effect in inducing immune responses in animal experiments. However, the effect of tumor vaccines in clinical trials is not ideal. Therefore, it is urgent to improve the existing tumor vaccines for tumor treatment. Here, we developed a fusion cell membrane (FCM) nano-vaccine FCM-NPs, which is prepared by fusing DCs and OC cells and coating the FCM on the poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with the immune adjuvant CpG-oligodeoxynucleotide (CpG-ODN). The fusion process promoted the maturation of DCs, thus up-regulating the expression of costimulatory molecule CD80/CD86 and accelerating lymph node homing of DCs. Furthermore, FCM-NPs has both the immunogenicity of tumor cells and the antigen presenting ability of DCs, it can stimulate naive T lymphocytes to produce a large number of tumor-specific cytotoxic CD8+ T lymphocytes. FCM-NPs exhibited strong immuno-activating effect both in vitro and in vivo. By establishing subcutaneous transplanted tumor model, patient-derived xenograft tumor model and abdominal metastatic tumor model, FCM-NPs was proved to have the effect of delaying the growth and inhibiting the metastasis of OC. FCM-NPs is expected to become a new tumor vaccine for the treatment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the context of tumor vaccines, LPS may improve antitumor immunity in part due to its ability to limit Tregs, which express TLR4 and may dampen the antitumor response ( 72 ). LPS is also used as an agent to mature DCs in vitro prior to pulsing with peptide antigens to enhance the antigen-presenting capacity of this cellular vaccine ( 73 ).…”

Section: Combination Strategies To Improve Cancer Vaccinesmentioning

confidence: 99%

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Hernandez

Malek

2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer vaccines offer the potential to enhance T cell-mediated antitumor immunity by expanding and increasing the function of tumor-specific T cells and shaping the recall response against recurring tumors. While the use of cancer vaccines is not a new immunotherapeutic approach, the cancer vaccine field continues to evolve as new antigen types emerge and vaccine formulations and delivery strategies are developed. As monotherapies, cancer vaccines have not been very efficacious in part due to pre-existing peripheral- and tumor-mediated tolerance mechanisms that limit T cell function. Over the years, various agents including Toll-like receptor agonists, cytokines, and checkpoint inhibitors have been employed as vaccine adjuvants and immune modulators to increase antigen-mediated activation, expansion, memory formation, and T effector cell function. A renewed interest in this approach has emerged as better neoepitope discovery tools are being developed and our understanding of what constitutes an effective cancer vaccine is improved. In the coming years, cancer vaccines will likely be vital to enhance the response to current immunotherapies. In this review, we discuss the various types of therapeutic cancer vaccines, including types of antigens and approaches used to enhance cancer vaccine responses such as TLR agonists, recombinant interleukin-2 and interleukin-2 derivatives, and checkpoint inhibitors.

show abstract

“…Immune adjuvants have been shown to be highly effective in enhancing antitumor immune responses and promoting radiation-induced ICD ( 93 – 95 ). CpG oligodeoxynucleotide (CpG ODN) is a toll-like receptor 9 (TLR9) agonist, which is widely used as an immune adjuvant ( 96 , 97 ). Liu et al.…”

Section: The Application Of Hydrogel-based Local Drug Delivery System...mentioning

confidence: 99%

Recent progress of hydrogel-based local drug delivery systems for postoperative radiotherapy

Xie

Liu²,

Cai³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Surgical resection and postoperative radiotherapy remained the most common therapeutic modalities for malignant tumors. However, tumor recurrence after receiving such combination is difficult to be avoided because of high invasiveness and radiation resistance of cancer cells during long-term therapy. Hydrogels, as novel local drug delivery systems, presented excellent biocompatibility, high drug loading capacity and sustained drug release property. Compared with conventional drug formulations, hydrogels are able to be administered intraoperatively and directly release the entrapped therapeutic agents to the unresectable tumor sites. Therefore, hydrogel-based local drug delivery systems have their unique advantages especially in sensitizing postoperative radiotherapy. In this context, classification and biological properties of hydrogels were firstly introduced. Then, recent progress and application of hydrogels for postoperative radiotherapy were summarized. Finally, the prospects and challenges of hydrogels in postoperative radiotherapy were discussed.

show abstract

Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy

Cited by 20 publications

References 41 publications

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

Recent progress of hydrogel-based local drug delivery systems for postoperative radiotherapy

Contact Info

Product

Resources

About